<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEO POLYCIN- neomycin sulfate, polymyxin b sulfate and bacitracin zinc ointment </strong><br>Paddock Laboratories, LLC<br></p></div>
<h1>Neo-Polycin® neomycin and polymyxin B sulfates and bacitracin zinc Ophthalmic Ointment USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_db6c750f-d2fb-4591-bc63-2123085de597"></a><a name="section-1"></a><p></p>
<p class="First">STERILE</p>
<p>Rx Only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_286722bd-8e2c-4896-bbb5-0cbffdb81f1f"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is a sterile antimicrobial ointment for ophthalmic use. Each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, bacitracin zinc equivalent to 400 bacitracin units in a white petrolatum and mineral oil base.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces </span><span class="Italics">fradiae</span> Waksman (Fam. <span class="Italics">Streptomycetaceae</span>). It has a potency equivalent of not less than 600 μg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<div class="Figure">
<a name="id163060021"></a><img alt="Chemical Structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf18b051-b656-4f46-8b69-a1df6f5d8d29&amp;name=cf18b051-b656-4f46-8b69-a1df6f5d8d29-01.jpg">
</div>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span>, which are produced by the growth of <span class="Italics">Bacillus </span><span class="Italics">polymyxa</span> (Prazmowski) Migula (Fam. <span class="Italics">Bacillaceae</span>). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<div class="Figure">
<a name="id144710753"></a><img alt="Chemical Structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf18b051-b656-4f46-8b69-a1df6f5d8d29&amp;name=cf18b051-b656-4f46-8b69-a1df6f5d8d29-02.jpg">
</div>
<p>Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the <span class="Italics">licheniformis</span> group of <span class="Italics">Bacillus </span><span class="Italics">subtilis</span> var Tracy. It has a potency of not less than 40 bacitracin units per mg. The structural formula is:</p>
<div class="Figure">
<a name="id-2101319320"></a><img alt="Chemical Structure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf18b051-b656-4f46-8b69-a1df6f5d8d29&amp;name=cf18b051-b656-4f46-8b69-a1df6f5d8d29-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_3051f370-114a-45cd-a49a-672225dc3ce7"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin.</p>
<p>Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code.</p>
<p>Polymyxin B is bactericidal for a variety of gram-negative organisms. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.</p>
<p>Bacitracin is bactericidal for a variety of gram-positive and gram-negative organisms. It interferes with bacterial cell wall synthesis by inhibition of the regeneration of phospholipid receptors involved in peptidoglycan synthesis.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="ID_d4eae320-f09b-4fec-b2e0-817554d79bd3"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology:</h2>
<p class="First">Neomycin sulfate, polymyxin B sulfate, and bacitracin zinc together are considered active against the following microorganisms: <span class="Italics">Staphylococcus </span><span class="Italics">aureus</span>, streptococci including <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus</span><span class="Italics"></span><span class="Italics">influenzae</span>, <span class="Italics">Klebsiella</span><span class="Italics">/</span><span class="Italics">Enterobacter</span> species, <span class="Italics">Neisseria</span> species, and <span class="Italics">Pseudomonas </span><span class="Italics">aeruginosa</span>. The product does not provide adequate coverage against <span class="Italics">Serratia</span><span class="Italics"></span><span class="Italics">marcescens</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_e0c49387-5211-475d-ad01-5ad6e4c0a5b5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Neo-Polycin® Ophthalmic Ointment is indicated for the topical treatment of superficial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the external eye and its adnexa caused by susceptible bacteria. Such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> encompass <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span> and <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_bd4526c0-f0a6-470a-90d8-911358f76a92"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Neo-Polycin® Ophthalmic Ointment is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_ffaef6bd-a418-4981-9b25-c8099a0298fc"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p>Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication.</p>
<p>Application of products containing these ingredients should be avoided for the patient thereafter (see <span class="Bold">PRECAUTIONS: General</span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_506ceaf6-0dac-4939-9b91-c0e1d1231fcc"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_75461de7-92bb-487a-bea2-67e65458a153"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">As with other antibiotic preparations, prolonged use of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment may result in overgrowth of nonsusceptible organisms including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate measures should be initiated. <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment may also develop. If <span class="product-label-link" type="condition" conceptid="4145093" conceptname="Purulent discharge">purulent discharge</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> becomes aggravated, the patient should discontinue use of the medication and consult a physician. There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (see <span class="Bold">PRECAUTIONS: Information for Patients</span>). Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: Kanamycin, paromomycin, streptomycin, and possibly gentamicin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_16e56512-b412-4bdf-9b96-e284839fad45"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. The use of this product by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated products (see <span class="Bold">PRECAUTIONS: General</span>). If the condition persists or gets worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> develops, the patient should be advised to stop use and consult a physician. Do not use this product if you are allergic to any of the listed ingredients. Keep tightly closed when not in use. Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_d6097af0-45e6-4f53-aa05-95195f3504be"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin. Treatment of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 μg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. No adverse effects on male or female fertility, litter size, or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_27173ae2-bafc-4936-a6c8-4fe1760084f1"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy:</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_cf7c2e4c-d4ae-4d0d-96a3-8b8e75822bb5"></a><a name="section-7.5"></a><p></p>
<h2>Teratorgenic Effects:</h2>
</div>
<div class="Section">
<a name="ID_0fcc2050-266a-4a6b-a0de-aa7893cb80b3"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy Category C.</h2>
<p class="First">Animal reproduction studies have not been conducted with neomycin sulfate, polymyxin B sulfate or bacitracin. It is also not known whether neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Neoymcin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_4544474d-2c62-4904-9b9b-3d090d001ac4"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_c05752d7-bd63-4d75-88b7-2997e4c24bc3"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_8a820a57-4d5c-4e45-856c-596bfb64fc4e"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_c9510d33-9e9c-4c33-9636-7b2fca989b69"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions have occurred with the anti-infective components of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <span class="Bold">WARNINGS</span>). More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely. Local irritation on instillation has also been reported.</p>
<p><span class="Italics">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Italics">Perrigo</span><span class="Italics"> at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_1307f428-7cf0-44ba-8aa6-bf4fd56e98aa"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">May be applied every 3 or 4 hours for 7 to 10 days, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_87e1ef6a-de3f-4066-b61a-05831609d539"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Neo-Polycin® Ophthalmic Ointment is supplied in 3.5 g (1/8 oz) sterile tamper evident tubes with ophthalmic tip.</p>
<p>NDC 0574-<span class="Bold">4250</span>-35</p>
<p>Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Neo-Polycin is a Registered Trademark of Perrigo Company</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d2d9407e-feb8-4162-89d1-0c3a0a2cdf4d"></a><a name="section-11"></a><p></p>
<p class="First">Manufactured For Perrigo, Minneapolis, MN 55427</p>
<p>Ini0913 R0913</p>
<p>8T900 RC J1</p>
<p>Rev 11-13 A</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8849aad0-0431-4809-907f-a7b19f34aec0"></a><a name="section-12"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Carton</h1>
<p class="First">Rx Only</p>
<p>NDC 0574-<span class="Bold">4250</span>-35</p>
<p>STERILE</p>
<p>Neo-Polycin®</p>
<p>neomycin and polymyxin B sulfates and bacitracin zinc</p>
<p>Ophthalmic Ointment USP</p>
<p>NET WT 3.5 g (1/8 oz)</p>
<div class="Figure">
<a name="id649950300"></a><img alt="Neo-Polycin Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf18b051-b656-4f46-8b69-a1df6f5d8d29&amp;name=cf18b051-b656-4f46-8b69-a1df6f5d8d29-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c6facbb8-ec4d-48e3-96bf-ab6a658c4cc7"></a><a name="section-13"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Label</h1>
<p class="First">Rx Only</p>
<p>NDC 0574-<span class="Bold">4250</span>-35</p>
<p>STERILE</p>
<p>Neo-Polycin®</p>
<p>neomycin and polymyxin B sulfates and bacitracin zinc</p>
<p>Ophthalmic Ointment USP</p>
<p>NET WT 3.5 g (1/8 oz)</p>
<div class="Figure">
<a name="id2065056947"></a><img alt="Neo-Polycin Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf18b051-b656-4f46-8b69-a1df6f5d8d29&amp;name=cf18b051-b656-4f46-8b69-a1df6f5d8d29-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEO POLYCIN 		
					</strong><br><span class="contentTableReg">neomycin and polymyxin b sulfates and bacitracin zinc ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0574-4250</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">10000 [USP'U]  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BACITRACIN ZINC</strong> (BACITRACIN) </td>
<td class="formItem">BACITRACIN</td>
<td class="formItem">400 [USP'U]  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0574-4250-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA060764</td>
<td class="formItem">01/05/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Paddock Laboratories, LLC
							(967694121)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cf18b051-b656-4f46-8b69-a1df6f5d8d29</div>
<div>Set id: cf18b051-b656-4f46-8b69-a1df6f5d8d29</div>
<div>Version: 1</div>
<div>Effective Time: 20140108</div>
</div>
</div> <div class="DistributorName">Paddock Laboratories, LLC</div></p>
</body></html>
